Business
Theravance Biopharma Reports Phase 3 CYPRESS Study Did Not Meet Primary Endpoint; Board Accelerates Strategic Review and Announces Cost Reduction Actions
Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH) today announced topline results from the Phase 3 CYPRESS study evaluating the efficacy and safety of ampreloxetine in patients with symptomatic neurogenic orthostatic hypotension (nOH) due to multiple system atrophy (MSA), a rare disease. The study did not meet its primary endpoint in the Orthostatic Hypotension Symptom Assessment (OHSA) composite score. As a result of this outcome, the Company has decided to win
About this update from Theravance Biopharma, Inc.
[{"type":"list","items":[{"val":[{"type":"text","content":"Phase 3 CYPRESS study did not meet the primary endpoint, the OHSA Composite Score, a patient reported outcome (PRO)","length":115,"tagName":"p"}]},{"val":[{"type":"text","content":"Cash of $326.5 million at Q4 2025 (no debt); approximately $400 million expected at end of Q1 2026 including receipt of 2025 milestones; Theravance highly confident in achieving $100 million 2026 TRELEGY milestone1","length":219,"tagName":"p"}]},{"val":[{"type":"text","content":"Strategic Review Committee accelerating ongoing efforts to evaluate alternatives to maximize shareholder value","length":110,"tagName":"p"}]},{"val":[{"type":"text","content":"Organizational restructuring to reduce cost base by approximately 60% (or approximately $70 million); expected to result in the Company generating approximately $60 - $70 million of annualized cash flow","length":202,"tagName":"p"}]},{"val":[{"type":"text","content":"Streamlined portfolio focused on YUPELRI®, a growing product to treat COPD with durable cash-flow generation and long-dated intellectual property protection in the U.S. into 2039; FY 2025 net sales $266.6 million recognized by Viatris (+12% YoY)2","length":246,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":892,"olType":false},{"type":"text","content":"DUBLIN, March 3, 2026 /PRNewswire/ -- Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH) today announced topline results from the Phase 3 CYPRESS study evaluating the efficacy and safety of ampreloxetine in patients with symptomatic neurogenic orthostatic hypotension (nOH) due to multiple system atrophy (MSA), a rare disease. The study did not meet its primary endpoint in the Orthostatic Hypotension Symptom Assessment (OHSA) composite score. As a result of this outcome, the Company has decided to wind down the ampreloxetine program.","length":601,"tagName":"p"},{"type":"image","alt":"Theravance Biopharma Logo (PRNewsfoto/Theravance Biopharma, Inc.)","displaySize":"","headline":null,"caption":"Theravance Biopharma Logo (PRNewsfoto/Theravance Biopharma, Inc.)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":94,"url":"https://media.zenfs.com/en/prnewswire.com/4d2df003249986704ef2ebec0198a9bd"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/TieX...